Skip to main content
Fig. 5 | Allergy, Asthma & Clinical Immunology

Fig. 5

From: Efficacy and safety of setipiprant in seasonal allergic rhinitis: results from Phase 2 and Phase 3 randomized, double-blind, placebo- and active-referenced studies

Fig. 5

Linear relationship between setipiprant daily dose and change from baseline in rDNSS during Phase 2 dose-ranging trial. Black dots represent the observed response (change from baseline in rDNSS) for each dose assessed; solid black line represents the dose–response model selected from multiple comparison goodness-of-fit modeling; blue lines represent 95% confidence limits, and the blue symbol is the calculated dose providing minimally clinically relevant effect (dashed horizontal line)

Back to article page